We then examined the relationship between the expression levels of these genes and the clinicopathological features and long-term outcomes to evaluate the clinical significance of GGH and FPGS mRNA expression in gastric cancer tissue in patients with Stage II/III gastric cancer undergoing postoperative adjuvant chemotherapy with S-1. This evidence concerns the gene FPGS and gastric cancer.